|Revision ID||Type||Time Submitted||Versioning Comment|
|135||Therapy||08/08/2017 3:30 PM||New interpretation|
|Variant(s)||MET copy number gain|
|Tumor(s)||Non-Small Cell Lung Carcinoma|
Ou SH, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6(5):942-6
Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The IPM makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and the IPM assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.